Day: September 19, 2025

GIG HARBOR, Wash., Sept. 19, 2025 (GLOBE NEWSWIRE) — Heritage Distilling Holding Company, Inc. (Nasdaq: CASK) (the “Company”) today announced that it will change its ticker symbol on the Nasdaq Capital Market (“Nasdaq”) from “CASK” to “IPST”, effective at the opening of trading on Monday September 22, 2025. The CUSIP number for the Company’s common stock will remain unchanged. The new ticker reflects the Company’s strategic focus on its $IP token treasury strategy and the $80 trillion intellectual property economy. No action is required by current stockholders. Shares of the Company’s common stock will continue to be listed and traded on Nasdaq. Additional details regarding the Company’s strategy and results of its recent Special Meeting of Stockholders will be provided in a separate press release expected to be issued on Monday...

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced the launch of a new $20 million Ordinary Share repurchase program (the “new repurchase program”), following the end of the creditor objection period, as announced by the Company on August 15, 2025. Nexxen has completed its previous $50 million Ordinary Share repurchase program and the new repurchase program is expected to continue until the earlier of March 19, 2026, or completion. The new repurchase program does not obligate Nexxen to repurchase any particular amount of Ordinary Shares and the program may be suspended, modified, or discontinued at any time at the Company’s discretion, subject to applicable...

Sixth Beyond Hello Location in Ohio and 41st Retail Location Nationwide New Dispensary Opens September 19th in Parma, Just South of Cleveland Grand Opening Celebration with Exclusive Promotions September 19 – October 4, 2025A Media Snippet accompanying this announcement is available by clicking on this link. BOCA RATON, Fla., Sept. 19, 2025 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, today announced the grand opening of its Beyond Hello™ Parma dispensary located at 6891 Ridge Rd, Parma, OH 44129. Beyond Hello Parma marks the Company’s 6th store in the state of Ohio joining Cincinnati, Toledo, Oxford, Warren and Mansfield, and the 41st operating retail location nationwide.The new dispensary will officially open...

neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (>15 kg) living with severe allergic reactions Alfresa Holdings, which owns the rights to market neffy in Japan, expects availability in Q4 2025 SAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that the Pharmaceuticals and Medical Devices Agency (PMDA), the Japanese authority responsible for the scientific review of drugs and medical devices, has granted approval for neffy® (epinephrine nasal spray) 1 mg and 2 mg doses, for the emergency treatment of allergic reactions...

KH Group PlcInside information 19 September 2025 at 3.20 pm EEST Inside information: Carl Haglund appointed as CEO of KH Group Plc KH Group Plc (”KH Group” or the ”Company”) has appointed Carl Haglund, M.Sc (Econ.), as the new CEO of the Company. Haglund is currently a member of the Board of Directors of the Company. Haglund has also served for many years as Chair of the Board of Directors of Nordic Rescue Group Oy (“Nordic Rescue Group”), a subsidiary of KH Group. Haglund takes up his new position as CEO of the Company as of today 19 September 2025. Haglund will step down from the Board of Directors of the Company as of today but will continue as Chair of the Board of Directors of Nordic Rescue Group. The Board of Directors of KH Group will otherwise continue without changes to its composition. Haglund has served as CEO of Veritas Pension...

Vancouver, Canada, Sept. 19, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has entered into securities purchase agreements (the “SPAs”) with institutional investors (the “Holders”). Pursuant to the SPAs, the Company may issue and sell, from time to time, convertible promissory notes (the “Notes”) in an aggregate principal amount of up to $10,000,000. Upon the execution of the SPAs (the “First Initial Closing”), the Company issued and sold to the Holders initial Notes in the aggregate principal amount of $555,556 for a purchase price of $500,000. Aegis Capital Corp. acted as financial...

Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four years1 Subcutaneous Lunsumio has potential to substantially reduce treatment administration time with an approximately one minute injection, compared with 2-4 hours IV infusion If approved, Lunsumio would be the first treatment available for people with follicular lymphoma after two or more lines of systemic therapy, which is both fixed-duration and subcutaneously administeredBasel, 19 September – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a subcutaneous (SC) formulation of Lunsumio® (mosunetuzumab) for the treatment of adult patients with relapsed or refractory...

Ra’anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced the submission of its full pre-submission (Pre-Sub) package to the U.S. Food and Drug Administration (FDA) for its PL-14 product, designed to help individuals suffering from nasal allergies. The submission includes comprehensive documentation covering manufacturing plans, clinical development strategies, and regulatory pathways. This submission represents a significant progress in Polyrizon’s regulatory strategy, paving the way for potential marketing clearance and addressing a critical unmet need in allergy treatment. Polyrizon’s PL-14 Allergy Blocker is a novel, non-invasive nasal spray that forms a physical barrier designed...